Collectively, these data demonstrate that patients who had tumours that coexpressed caveolin-1 and an activated AKT/mTOR pathway have significantly shorter recurrence-free survival than those patients who had tumours that expressed caveolin-1 alone or activated AKT/mTOR components alone (Figure 3 and Table 2B). Here, MTOR is linked to neoplasm.